|
|
Article: Data challenged; ALLHAT study is flawed, PI says.
- Article from:
- Biotech Week
- Article date:
- January 29, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 JAN 29 - (NewsRx.com & NewsRx.net) -- GenoMed, Inc., announced that the ALLHAT study published in a recent issue of Journal of the American Medical Association has a fatal research flaw.
ALLHAT, an 8-year study funded by the National Institutes of Health at a cost of over $100 million and involving over 40,000 patients, concluded that lowering blood pressure with a thiazide diuretic was just as effective as therapy with lisinopril, an ACE inhibitor. An editorial in the same issue of JAMA by Lawrence J. Appel admitted that this result was surprising.
GenoMed has evidence that lisinopril failed to work better than a thiazide diuretic for 2 important ...